Advertisement
Exelixis, Inc.

Exelixis, Inc. (EXEL) Stock Overview

Explore Exelixis, Inc.’s financial performance, market position, analyst ratings, and future outlook.

EXELNASDAQ
HealthcareBiotechnology
$52.87
$1.53(2.98%)
U.S. Market opens in 7h 45m
Advertisement

Exelixis, Inc. (EXEL)

Meyka AI Score

Z

Key Financials

Market Cap13.3B
P/E Ratio16.95
EPS (TTM)$3.02
ROE0.40%
Fundamental Analysis

AI Price Forecasts

1 Month$55.92
3 Months$46.95
1 Year Target$55.43

EXEL Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Exelixis, Inc. (EXEL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 59.00, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $55.43.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 16.95 and a market capitalization of 13.3B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
2.98%
5-Day Change
1.67%
1-Month Change
5.42%
3-Month Change
27.18%
6-Month Change
13.67%
Year-to-Date (YTD) Change
20.63%
1-Year Change
15.64%
3-Year Change
171.69%
5-Year Change
131.28%
All-Time (Max) Change
258.44%

Contact Information

650 837 7000
1851 Harbor Bay Parkway, Alameda, CA, 94502

Company Facts

11,470 Employees
IPO DateApr 17, 2000
CountryUS
Actively Trading

Frequently Asked Questions